Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Geoffrey Hill

Nurse Practitioner, Pediatrics Upper Arlington, OH Nurse Practitioner

NPI 1437795978 CMS profile 11062818

3300 Riverside Dr, Upper Arlington, OH 43221

Open in the dashboard

General payments

$5,306

371 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Geoffrey Hill of Upper Arlington, OH is reported in the CMS Open Payments database as having received $5,306 across 371 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $880 61
2024 General $1,417 71
2023 General $1,109 77
2022 General $1,071 81
2021 General $828 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Geoffrey Hill
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Geoffrey Hill were reported at $880. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Geoffrey Hill Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $828 $60 $23–$142 $132
2022 $1,071 $72 $27–$161 $149
2023 $1,109 $89 $35–$185 $160
2024 $1,417 $93 $34–$199 $164
2025 $880 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Supernus Pharmaceuticals, Inc. $1,947 120 payments
  2. Corium, Inc. $800 45 payments
  3. Tris Pharma Inc $732 83 payments
  4. Neos Therapeutics, LP $437 40 payments
  5. Ironshore Pharmaceuticals Inc. $408 26 payments
  6. kaleo, Inc. $194 11 payments
  7. Merck Sharp & Dohme Corporation $144 8 payments
  8. Nestle HealthCare Nutrition Inc. $132 8 payments
  9. Seqirus USA Inc $101 5 payments
  10. Pfizer Inc. $50 3 payments
  11. Other $360 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,306 371 payments
Products named General payments · program years 2021–2025
  1. Qelbree Viloxazine Hydrochloride $1,274 73 payments
  2. Azstarys $800 45 payments
  3. QELBREE Psychology $673 47 payments
  4. Dyanavel XR Adhd $340 38 payments
  5. Dyanavel XR Adhd $319 39 payments
  6. JORNAY PM $310 21 payments
  7. COTEMPLA XR-ODT $266 25 payments
  8. Adzenys XR-ODT $213 21 payments
  9. AUVI-Q $155 9 payments
  10. ZENPEP $152 9 payments
  11. Other $1,475 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

371 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Pediatrics in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record